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Background and purpose   The natural pattern of bone healing 
in large bony defects following curettage alone as treatment of 
benign bone tumors around the knee is not well reported. We ana-
lyzed the outcome in 146 patients.
Patients and methods   146 patients with over 18 months of fol-
low-up who underwent curettage without bone substitute filling 
or bone grafting for a benign tumor in the distal femur or upper 
tibia were included. The mean diameter of the defects following 
curettage was 5.7 (1.3–11) cm and the estimated average volume 
was 63 (1–240) cm3. The plain radiographs before and following 
curettage were reviewed to establish the size of the initial defect 
and the rate of reconstitution and infilling of the bone. The time to 
full weight bearing and any complications were recorded.
Results   There was a variable rate of infilling; some defects 
completely  reconstituted  to  a  normal  appearance  while  some 
never filled in. In 88% of the cases, no further intervention after 
curettage was required and the mean time to full weight bearing 
was 6 weeks. The risk of subsequent fracture or the late develop-
ment of osteoarthritis was strongly related to the size of the cyst at 
diagnosis, with cysts of > 60 cm3 (about 5 cm in diameter) having 
a much higher incidence of complications.
Interpretation   This study demonstrates the natural healing 
ability of bone without any adjuvant filling. It could be used as a 
baseline for future studies using any sort of filling with autograft, 
allograft, or bone substitute. 

The management of benign bony defects has been the subject 
of much debate between orthopedic surgeons in recent years. 
There  has  been  an  increasing  trend  towards  intraoperative 
filling of these lesions, and this is especially so when deal-
ing with defects in weight-bearing areas. Large bone cavities 
have been reinforced with autologous bone grafts, allografts, 
poly(methylmethacrylate) (PMMA) bone cement, and bone 
substitutes (Mjöberg et al 1984, Ryan and Begeman 1984, 
Sethi et al. 1993, Finkemeier 2002, Malek et al. 2006). These 
methods may have several limitations due to the limited avail-
ability of autograft and the low risk of disease transmission 
associated with the use of allograft (Tomford 1995). PMMA 
cement may provide instant stability, but it is not the most bio-
logical method for filling of bone (Mjöberg el al. 1984). There 
is also concern that when used near the surface of a joint, it 
may cause thermal injury and damage chondrocytes (Dunne 
and Orr 2002). Many different bone substitutes, aimed at fill-
ing these defects (Finkemeier 2002), are flooding the market; 
yet, there is very little evidence for their efficacy and there 
have been very few comparisons with the normal degree of 
healing expected in bone defects (Virolainen et al. 1997, Lem-
perle et al. 1998, Kopylov et al. 2002). Despite the fact that 
there is a strong capacity to create new bone after trauma, 
there have been very few studies reporting on the ability of a 
surgically created bone defect to fill in if left empty (Medige 
et al. 1982, Virolainen et al. 1997, Lemperle et al. 1998). The 
paucity of data on the natural history of bone defects aroused 
our interest. In a retrospective study, we thus investigated the 
outcome of 146 benign bony tumors about the knee that had 
been treated with curettage alone without any augmentation. 
Patients and methods
We identified 146 patients with benign bone tumors about the 
knee who had undergone curettage without grafting or other 
filling of the defect. These patients had been treated at the 
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2003. The data were gathered from medical records and all 
the patient radiographs were examined to determine whether 
there had been healing of the defect or whether complications 
had developed.
The criteria for inclusion were a histologically confirmed 
solitary  benign  lesion  around  the  knee,  with  no  previous 
surgery treated with curettage, with no augmentation of the 
defect, and with at least 18 months of follow-up. 
The mean age of the patients was 28 (1–71) years; 43 were 
under 16 years of age at the time of treatment. There were 83 
males and 63 females. The average follow-up was 4 (1.5–20) 
years.  The  most  common  histological  diagnosis  was  giant 
cell tumor in 68 patients, followed by chondroblastoma in 21 
(Table 1).
Surgery  involved  intralesional  curettage  through  a  gen-
erous  cortical  window  followed  by  burring,  brushing,  and 
pulse  lavage  of  the  lesion. After  surgery  every  cavity  was 
left empty without any augmentation, and drains were not 
inserted. Patients were asked to undertake partial weight bear-
ing for 2–10 weeks, depending on the size of the cyst and the 
radiological features. All were on full weight bearing after 10 
weeks.
The pre- and postoperative radiographs were examined and 
measurements  of  size  and  estimates  of  consolidation  were 
made and documented sequentially. The presence of osteoar-
thritic changes or fractures was also noted. 
The volume calculations were done as follows, where A = 
width, B = depth, and C = height.   
Cylinder defect = ABC × 0.785, i.e. (π × A/2 × B/2 × C).
Spherical defect = ABC × 0.52, i.e. (4/3 × π × A/2 × B/2 × C/2). 
The most appropriate of the two formulae was used, depend-
ing on the perceived shape of the defect. 
Statistical significance was analyzed using the chi-squared 
test and Mann-Whitney U test. A value of p < 0.05 was con-
sidered significant.
The outcomes were based on radiographic consolidation of 
the lesions along with subjective clinical assessment and func-
tion recorded in the patient records.
 
Results
129 of the cysts (88%) were within 15 mm of the surface of 
the joint. 104 of the cysts (71%) were located in the tibia and 
42 were in the femur. A medial location of the cyst was most 
common in both the tibia and femur (Table 2). 
The mean maximum diameter of the cysts was 5.7 (1.3–11) 
cm and the mean volume of the lesions was 63 (1–240) cm3. 
The femoral cysts were larger than the tibial ones (p = 0.05) 
(Table 3). 64 of the cysts had a maximum diameter of 5 cm or 
less, while 82 had a diameter of more than 5 cm. 
6 patients had preoperative fractures and 14 had postopera-
tive fractures through the cyst, all within 2 months of their 
operation. All 14 postoperative fractures were in patients with 
giant cell tumors. Only 2 fractures required internal fixation; 
all the others were stable fractures and were treated nonop-
eratively in plaster with restriction of weight bearing. There 
was no correlation between preoperative fracture and size of 
the cyst, but 4 of the 6 arose in patients with giant cell tumors 
and 4 arose in lateral locations—2 in the tibia and 2 in the 
femur. There was, however, a strong correlation between risk 
of postoperative fracture and both the size and volume of the 
cyst. The average size of the cysts that fractured postopera-
tively was 108 cm3, as compared to 58 cm3 for the cysts that 
did not fracture (p = 0.003). The risk of fracture was 5% in 
patients with cysts less than 60 cm3, as compared to 17% for 
those with cysts larger than 60 cm3 (p = 0.01). The risk was 
3% when the maximum diameter of the cyst was ≤ 5 cm, but 
15% when the diameter was > 5 cm (p = 0.02).
16 patients (11%) developed local recurrences during the 
period of follow-up, with the risk of local recurrence being 
15% for giant cell tumours and 16% for aneurysmal bone 
cysts. 10 patients had repeated curettage, 2 required subse-
quent augmentation with cement, and 4 had endoprosthetic 
replacement. 
The average time to bone healing, as judged by allowing full 
Table 3. The mean volume of the cysts (cm3) accord-
ing to the anatomical location
  Mean  Medial  Central  Lateral
Femur  78  92  42  72
Tibia  51  49  71  54
Table 1. Histological diagnosis of the 146 tumors
    No.  %
GCT  68  47
Chondroblastoma  21  14
ABC  19  13
Enchondroma  9  6
Fibrous dysplasia  5   4
Others  24  16
 
Table 2. The anatomical location of the cysts
  Medial  Central  Lateral
Femur  22  6  14
Tibia  47  27  306  Acta Orthopaedica 2009; 80 (1): 4–8
weight bearing, was 6 (2–10) weeks. The mean time to full 
weight bearing was 5.4 weeks for patients with cysts up to 5 
cm in diameter and 6.7 weeks for those with cysts over 5 cm (p 
= 0.003). Although there was a trend for older patients to take 
slightly longer to progress to full weight bearing, this was not 
statistically significant.
None of the patients required bone grafting or a further 
surgical procedure unless they developed a fracture or local 
recurrence. Review of serial radiographs showed that while 
the smaller cysts filled up completely, the larger ones tended 
to heal initially by thickening of the cortex and then by devel-
opment of septae running across the defect. This appearance 
remained unchanged for years.
During the course of follow-up, 16 knees showed radio-
graphic  changes  consistent  with  osteoarthritis.  2  of  these 
patients had preoperative pathological fractures while 2 others 
had postoperative fractures. 9 of the 16 patients had symptoms 
attributable to the osteoarthritis. 7 suffered from a persistent 
stiff knee with pain, and 2 suffered from chronic pain only. 
The rest of the patients who developed osteoarthritis were 
still asymptomatic at the time of the study. There was a strong 
correlation between incidence of degenerative changes and 
tumor size; these changes arose in 13 of 59 patients with a 
cyst greater than 60 cm3 but only in 3 of 87 patients with cysts 
smaller than 60 cm3 (p = 0.004). All but one of these patients 
who had radiographic osteoarthritis had a giant cell tumor. 
The risk of structural complications (fracture or osteoarthritis) 
was thus strongly associated with the size of the cyst at the 
time of diagnosis. 24 patients of the 59 with a cyst greater than 
60 cm3 developed either or both of the structural complica-
tions, as compared to 8 of the 87 patients with a smaller cyst 
(p < 0.0001). 
Only 9 patients (6%)—all of whom had large cysts (> 60 
cm3)—did not achieve good function with a satisfactory range 
of knee movement and no pain when walking. 
Discussion
Cure rates of 95% have been achieved using curettage as the 
sole treatment in benign bony lesions, although in some cases 
the curettage had to be repeated (Kreicbergs et al. 1985). The 
overall recurrence rates may vary quite considerably, depend-
ing on the histology of the disease (O’Donnell et al. 1994). 
In giant cell tumors treated by curettage with adjuvant filling, 
recurrence rates have varied between 7–50% (Blackley et al. 
1999, Trieb et al. 2001, Saiz et al. 2004, Zhen et al. 2004, 
Prosser et al. 2005, Malek et al. 2006, Vult von Steyern et al. 
2006). There have been many attempts to try to reduce this 
rate of local recurrence, including the use of adjuvants such 
as phenol, cryotherapy, and bone cement (Turcotte et al. 2002, 
Zhen et al. 2004, Szalay et al. 2006). Although individual cen-
ters have claimed good results using a variety of techniques, 
large population studies have failed to show that any one tech-
nique is better than any other and to date there have been no 
randomized controlled trials investigating this, even though 
several authors have suggested such (Capanna et al. 1985, 
Trieb et al. 2001, Turcotte et al. 2002, Prosser et al. 2005). 
The use of PMMA cement was advocated on the basis that not 
only would it fill the defect and supply structural support, but 
it might also give benefit through its thermal effect on residual 
tumor cells, but most large series have failed to show con-
vincingly that local control is better with or without cement 
(O’Donnell  et  al.  1994,  Turcotte  et  al.  2002). All  authors 
agree, however, that adequate exposure and detailed curettage 
is essential to maximize local control, whether adjuvants are 
used or not (Blackley et al. 1999, Turcotte et al. 2002). 
Curettage is also used for the treatment of other benign 
cysts, and the question of whether adjuvants are necessary has 
also been raised for both aneurysmal bone cysts and chond-
roblastoma (Cottalorda and Bourelle 2006, van der Geest et 
al. 2007).
Our policy of curettage alone without adjuvants appears jus-
tified as our rates of local control are well within those reported 
from other centers. We, too, believe that a randomized con-
trolled trial should be done to try to resolve this question.
Equally contentious is the decision as to what to do with the 
defect that is created following curettage. There is a natural 
tendency to wish to fill it with something, but again there is no 
evidence to show what is best—and there is also no evidence 
to suggest that filling the defect improves the chances of local 
control. Our policy of leaving these cavities empty was based 
initially on the observation that small defects in bone filled in 
perfectly well without any aid, and our present data show that 
even worryingly large defects will reform. There is, however, 
a strong correlation between the risk of subsequent complica-
tions such as fracture or osteoarthritis and the size of the cyst 
at the time of diagnosis. In our experience, cysts larger than 
60 cm3 (i.e. cysts of 5 cm or more) have the greatest risk of 
complications and cysts smaller than this have a low risk.
Apart from bone cement, most substances that are used to 
fill defects of this sort have no inherent strength and rely upon 
bone ingrowth for strength (e.g. cancellous allograft, cancel-
lous autograft, most bone substitutes). Thus, these patients will 
be as much at risk of fracture or collapse of the joint surface 
as those without any filling, until the bone has consolidated. 
Again, there is no evidence to show that this happens more 
quickly if bone graft or bone substitute is used.
None of the currently available materials for filling bone 
defects of this sort are without problems. We have shown that 
small defects (under 60 cm3, i.e. approximately less than 5 
cm) have few problems if they are left empty, and so it is only 
the larger defects that are likely to need filling. Obtaining more 
than 60 cm3 of autograft is quite a large operative procedure, 
which is likely to lead to significant morbidity. There may be 
reluctance to use allograft, however, particularly in children or 
young people. Bone substitutes have become more and more 
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in defects of this size (Buma et al. 1996, Finkemeier 2002).
Bone substitutes might be safer, in the sense that they do 
not transmit any viral diseases (except substitutes that have 
human or animal origin). It is often forgotten, however, that 
the most common life-threatening complication is infection 
and any foreign material can increase the risk of transmitting 
bacterial infection (Aspenberg 1998).
The market is full of many different kinds of bone substi-
tutes only waiting for a cyst to be filled. In the literature, most 
bone substitutes are compared with some other filling mate-
rial under optimal conditions. Many of these porous substi-
tutes have numerous advantages over autografts and allografts 
because of their unlimited supply, and easy sterilization and 
storage (Bucholz 2002), but most are quite expensive—partic-
provide a basis for further studies involving the treatment of 
benign bone cysts and suggest that these studies should con-
centrate on cysts larger than 5 cm.
We conclude from this study that most benign defects of 
bone will consolidate without supplementation. 
Most of the operations were performed by RG, SC, RT, and AA. Data were 
collected by MH, US, and SS. The manuscript was written by MH, US, and 
RG. RG also supervised the entire study.
The work of MH was supported in part by the competitive research funding of 
Pirkanmaa Hospital District. 
A 25-year-old woman with cylinder form giant cell tumor of 220 cm3. There was an 
intra-articular fracture preoperatively. Full weight bearing was allowed at 6 weeks after 
curettage.
The  same  patient  9  years  after  surgery.  She  developed  osteoarthritis  during  the 
follow-up.
ularly so when used to fill large defects. Most of 
them seem to incorporate well, and if structural 
support is not required the function is almost 
comparable with autograft for bone filling pur-
poses. There has, however, been a lack of studies 
in which bone substitutes have been compared 
to the spontaneous healing of bone. The blood 
circulation  is  good  in  cancellous  bone,  pro-
moting spontaneous regeneration. Following a 
detailed curettage, the margins of the defect will 
always contain healthy cancellous bone—which 
will allow migrating osteoblasts to produce bone 
matrix in the haematoma that will fill the defect, 
a scenario very similar to that in fracture heal-
ing. 
There  are  experimental  data  showing  that 
bone defects that are left empty heal just as well 
as when filled with a bone substitute (Medige et 
al. 1982, Virolainen et al. 1997, Lemperle et al. 
1998). In our study, we did not obtain any his-
tological evidence of new bone formation in the 
cavities,  although  the  plain  radiographs  dem-
onstrate that the cavities were still visible even 
years after surgery (Figures). Even if the bone 
cavity did not reform completely, the cortical 
bone was thick enough to carry the load. Inside 
the cavity, there were smaller cavities divided by 
several new septa. 
All  the  postoperative  pathological  fractures 
happened during the first weeks after the sur-
gery,  and  not  when  full  weight  bearing  was 
allowed. This was also found to be the case in 
the experimental model of large persistent cysts 
(Medige et al. 1982). Full weight bearing and 
mechanical stress finalize the strength and the 
healing process of the injured bone (Medige et 
al. 1982, Isaksson et al. 2005). 
There is a need for prospective randomized 
studies to evaluate the effect of different filling 
materials on the remodeling of bone. Our data 8  Acta Orthopaedica 2009; 80 (1): 4–8
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